CX Institutional Purchases Shares of 34,768 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

CX Institutional purchased a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 34,768 shares of the specialty pharmaceutical company's stock, valued at approximately $4,316,000. CX Institutional owned 0.06% of Jazz Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of JAZZ. SG Americas Securities LLC bought a new position in shares of Jazz Pharmaceuticals in the first quarter worth approximately $1,173,000. GAMMA Investing LLC raised its position in Jazz Pharmaceuticals by 63.7% in the 1st quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company's stock worth $126,000 after purchasing an additional 395 shares during the period. Range Financial Group LLC purchased a new stake in Jazz Pharmaceuticals in the 1st quarter worth about $917,000. First Citizens Bank & Trust Co. bought a new position in Jazz Pharmaceuticals in the 1st quarter worth about $318,000. Finally, UMB Bank n.a. boosted its stake in shares of Jazz Pharmaceuticals by 116.4% during the first quarter. UMB Bank n.a. now owns 673 shares of the specialty pharmaceutical company's stock valued at $84,000 after purchasing an additional 362 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ traded down $1.79 during trading hours on Friday, reaching $108.50. The stock had a trading volume of 478,127 shares, compared to its average volume of 833,690. The stock has a market capitalization of $6.69 billion, a PE ratio of 15.28, a PEG ratio of 1.04 and a beta of 0.33. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a 50 day moving average price of $107.84 and a two-hundred day moving average price of $120.56. Jazz Pharmaceuticals plc has a 52 week low of $95.49 and a 52 week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. During the same quarter last year, the business earned $2.68 EPS. The business's revenue was down .5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Seamus Mulligan bought 100,000 shares of the firm's stock in a transaction on Friday, May 9th. The stock was bought at an average cost of $98.26 per share, for a total transaction of $9,826,000.00. Following the completion of the purchase, the director now directly owns 100,000 shares in the company, valued at approximately $9,826,000. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the transaction, the chief executive officer now directly owns 439,307 shares in the company, valued at $51,113,369.45. The trade was a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 3,000 shares of company stock valued at $355,925. Corporate insiders own 4.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on JAZZ. Barclays reaffirmed an "overweight" rating and issued a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday. Robert W. Baird decreased their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada decreased their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, HC Wainwright upped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $184.00.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.